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Purpose. Choroidal neovascularization (CNV) is often associated with age-related macular degeneration (AMD) and pathological
myopia (PM). Bisphosphonates, the drug of choice to treat osteoporosis, have been recently reported to have anti-angiogenic
eﬀects. The purpose of this study is to investigate the therapeutic eﬀects of oral bisphosphonates for CNV in humans. Methods.
Thirty-six consecutive cases with CNV due to AMD or PM who declined anti-VEGF therapy were recruited. The patients were
prescribed 5 mg of oral alendronates daily for 6 months. The best-corrected visual-acuity (BCVA), the lesion size in fundus
photographs and ﬂuorescein angiography, foveal thickness and total macular volume in optical coherence tomography were
compared between pre- and post-treatment. Results. The mean BCVA of the patients was signiﬁcantly improved after a months
with the treatment in the AMD group. In the PM group, the mean BCVA was maintained up to 6 months with the treatment.
The mean lesion size was signiﬁcantly decreased by 3 months in both groups. The averages of foveal thickness and total macular
volume were signiﬁcantly reduced after 1 month of treatment in the AMD group.Conclusions. Oral bisphosphonate should be
further investigated as a possible therapeutic and preventive drug for CNV due to AMD and PM.
1.Introduction
Choroidal neovascularization (CNV) is a major cause of
adult blindness and is often associated with age-related
macular degeneration (AMD) and pathological myopia or
other macular diseases. Current therapies for CNV are
representedbyrepeatedintravitrealinjectionsofantivascular
endothelial growth factor (VEGF) antibodies or aptamer
[1, 2]. They require periodic reinjections of the antibody
or aptamer every 4–6 weeks for many years to keep the
lesion stable and to maintain vision, or else visual acuity was
reported to be reduced [3]. These retreatments may pose a
cumulative risk for ocular and systemic complications such
as endophthalmitis and strokes [4–6] and pose a burden on
both the patients and health care systems. Hence, we are
interested in alternative therapies using oral drugs or eye
drops, since they are usually less expensive, easier to use to
treat a broad range of patients, and may also be used for
prevention [7].
Bisphosphonates are powerful inhibitors of osteoclasts,
and are commonly used as the drug of choice to treat and
prevent osteoporosis [8]. Recent studies have demonstrated
that the antitumor and antiangiogenic eﬀects induced by
suppressing VEGF expression are associated with bisphos-
phonates, which opens up novel possibilities for this drug
class and raises new areas of research for tumorigenesis and
angiogenesis [9–12]. However, in ophthalmology, bisphos-
phonates are known only as drugs that may cause uveitis,
scleritis, or orbital inﬂammation as rare side eﬀects [13–
15]. Although bisphosphonates were thought to accumulate
mostly in the bone tissue, we suspected that bisphosphonates
may have good permeability into the eye, even to the
point of causing side eﬀects in rare cases. Following these
insights, we recently demonstrated the inhibitory eﬀects of
bisphosphonates on laser-induced choroidal neovasculariza-
tion (CNV) due to suppressed VEGF expression in mice, and
hypothesized about the therapeutic eﬀects of this drug in
human CNV associated with AMD and related diseases [16].2 Journal of Ophthalmology
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Figure 1: Time-course of the LogMAR BCVA values with oral
bisphosphonates. Solid line; AMD, dashed line; myopic CNV. The
valuesarepresentedasmeans+SEM. ∗P<. 05.LogMAR:logarithm
of the minimum angle of resolution, BCVA: best-corrected visual
acuity.
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Figure 2: Change in lesion size with oral bisphosphonates. The
values are presented as means + SEM.
Therefore,weconductedapreliminaryprospectivestudy,
in which we administered oral bisphosphonates to 36 cases
of CNV secondary to AMD and pathological myopia, and
found that oral bisphosphonates signiﬁcantly inhibited CNV
in these patients.
2. Methods
The cohort included 40 eyes from 36 consecutive patients
with CNV secondary to AMD and pathological myopia (25
eyes of 24 AMD cases and 15 eyes of 12 pathological myopia
cases), who declined intravitreal injections of anti-VEGF
drugs or had systemic risks for strokes. Since both types of
CNV are known to respond to anti-VEGF therapy [1, 17],
we included both phenotypes in the present study. The CNV
was determined by slit-lamp biomicroscopes of the fundi,
50 degree color fundus photographs, optical coherence
tomographies (OCT) (Stratus or Cirrus OCT, Carl Zeiss
Meditec Japan, Tokyo, Japan), ﬂuorescein angiographies
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Figure 3: Time-course of the foveal thickness with oral bisphos-
phonates. Solid line; AMD, dashed line; myopic CNV. The values
are presented as means + SEM. ∗P<. 05, ∗∗P<. 01.
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Figure 4: Time-course of the total macular volume with oral
bisphosphonates. Solid line; AMD, dashed line; myopic CNV. The
values are presented as means + SEM. ∗P<. 01, ∗∗P<. 005,
∗∗∗P<. 001.
(FA) and indocyanine green angiography (ICG). All CNV
cases included subfoveal lesions accompanied by serous
retinal detachments and subretinal hemorrhages in this
study. The AMD cases (25 eyes) included all 3 lesion types,
namely, predominantly classic (6 eyes), minimally classic (11
eyes) and occult with no classic (8 eyes), lesions determined
by FA. Eleven cases with recurrent CNV once maintained by
photodynamic therapy (PDT) from 3 months to two years
agowerealsoincludedintheAMDcases.Casesofpolypoidal
choroidal vasculopathy (PCV) were diagnosed by ICG and
were excluded from this study since PCV is not thought as
typical CNV [34]. Pathological myopia was diagnosed by
an axial length over 26.5mm and the corresponding fundus
ﬁndings. No patients received prior treatment in the myopia
cases. The summarized clinical data of the enrolled patients
are shown in Table 1. The visual acuities were determined
using a Landolt C chart and were converted to a logarithm of
the minimum angle of resolution (LogMAR) for calculation
and description. The lesion size was analyzed by NIH image J
software using digital images. Speciﬁcally, the lesion size was
determined as the combined area of dye leakage at 5 minutes
in FA and hemorrhage in fundus photography and wasJournal of Ophthalmology 3
Table 1: Clinical data of CNV patients treated by oral bisphosphonate.
CNV type AMD Pathological myopia
Age (years) 76.0 ±9.06 4 .4 ±8.7
Gender (male/female) 20/4 2/10
Baseline LogMAR BCVA 0.75 ±0.46 0.53 ±0.34
BCVA: best corrected visual acuity, LogMAR: logarithm of the minimum angle of resolution.
(a) (b)
(c)
200μm
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Figure 5: A 61-year-old male showed CNV (arrows) due to AMD (a). Fluorescein angiography (FA) showed predominantly classic CNV
(c), and optical coherence tomography (OCT) revealed a subretinal lesion before treatment (e). After the oral administration of alendronate
for three months, the CNV regressed remarkably (b) and no leakage was observed using FA (d). A remarkable decrease in the size of the
subretinal lesion was observed using OCT (f).
quantiﬁed by the number of pixels. All subjects were masked
for patient ID, clinical course, and the date of examinations.
Under approval by the Kobe University institutional
review board and informed consent from all the patients,
5mgoforalalendronates(TeijinPharma.Ltd.,Tokyo,Japan)
were prescribed daily for six months. The patients were
informed about the side eﬀects of bisphosphonates (e.g.,
gastritis, arthralgia, uveitis) and were advised to consult their
physician if they felt any unusual symptoms. Medication
compliance was checked by interview and ophthalmo-
logical examinations, including the best-corrected visual-
acuity (BCVA), color fundus photographs, and OCT, which
were performed monthly. Fluorescein angiographies were
repeated at three months posttreatment.
T h eL o g M A RB C V Aw a se v a l u a t e da st h em a i no u t c o m e
of the treatment. The change in lesion size found from
fundus photographs and FA, the foveal thickness (average
of central 1mm circle), and the total macular volume4 Journal of Ophthalmology
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Figure 6: A 79-year-old male who received PDT for 27 months ago showed a recurrence of CNV (arrowheads), mainly at the temporal
edge of the old scar (arrows) (a). Fluorescein angiography (FA) showed predominantly classic CNV (c), and optical coherence tomography
(OCT) revealed a subretinal lesion before treatment (e). After the oral administration of alendronate for three months, the CNV became
subretinal ﬁbrosis (b) and no leakage was observed using FA (d). A remarkable decrease in the size of the subretinal lesion was observed
using OCT (f).
determined automatically by a 6mm retinal map from
Stratus OCT and by a 200 × 200 retinal map from Cirrus
OCT were also assessed over the treatment period. The OCT
system used in each patient was consistent throughout the
follow-up period.
For statistical analysis, Wilcoxon signed-rank test was
used for the BCVA, lesion size, foveal thickness, and total
macular volume. P values less than.05 were considered to be
statistically signiﬁcant
3. Results
Twenty-one eyes of 20 AMD cases were ultimately followed-
up for 6 months, since three cases self-discontinued and
one preferred photodynamic therapy after 3 months of
medication. Fourteen eyes of 11 pathological myopia cases
were followed-up for 6 months, but one case discontinued
medication after 3 months because of bilateral uveitis, which
resolved with topical steroids.
The mean BCVA of the patients was signiﬁcantly
improved after a month with the treatment in the AMD
group (Figure 1). Comparing the proportions of BCVA
between pretreatment and after 6 months of the treatment,
the number of eyes in which BCVA improved more than
0.2 LogMAR,, changed within 0.2 LogMAR and deteriorated
more than 0.2 LogMAR were 5 (24%), 15 (71%), and 1 (5%)
eyes, respectively in the AMD group, whereas those in the
pathological myopia group were 2 (14%), 9 (64%), and 3
(22%)eyes,respectively.Themeanlesionsizesdeterminedin
FA and fundus photograph were signiﬁcantly decreased after
3 months of the treatment in both groups (Figure 2). The
mean foveal thickness (Figure 3)a n dt o t a lm a c u l a rv o l u m e
(Figure 4) measured by OCT were signiﬁcantly decreased in
theAMDgroupafteramonthwiththetreatment.Noadverse
systemic side eﬀects were found or self-reported in any of the
present cases. The detailed ﬁndings from selected cases of the
responders are shown in Figures 5, 6,a n d7.
4. Discussion
In our preliminary study, we found that oral bisphospho-
nates stopped the progression of CNV due to AMD andJournal of Ophthalmology 5
(a) (b)
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Figure 7:A57-year-oldfemalewasreferredformyopicCNV(a).PredominantlyclassicCNVwasdetectedbyFA(c),andasub-retinallesion
with pigment epithelial detachment was found by OCT (e). With three months of oral alendronate administration, the lesion decreased
remarkably in size (b), and the dye leakage was attenuated as detected by FA (d). OCT showed a decrease in the size of the subretinal lesion
(arrows) (f).
pathological myopia in 40 eyesfrom36 patients. Their BCVA
was maintained for at least 6 months, and the measured
lesion size was signiﬁcantly reduced with the treatment. In
the AMD group, OCT revealed a signiﬁcant improvement in
fovealthicknessandtotalmacularvolumeatonemonthafter
the treatment, and further improvements were observed up
to 6 months with the treatment.
Although recent studies have demonstrated that antitu-
mor and antiangiogenic eﬀects are associated with bispho-
sphonates [9–12], in the ﬁeld of ophthalmology, they are
regarded only as drugs that may cause ocular inﬂammation
in certain individuals [13–15]. Therefore, this is the ﬁrst
study which reports beneﬁcial ocular eﬀects of bisphos-
phonates. CNV due to AMD and pathological myopia is a
representative idiopathic angiogenic disorder and a major
age-related disorder in addition to osteoporosis, and the
number of patients suﬀering from these pathologies has
increasedremarkablyoverrecentyears[18,19].Hence,many
elderly people face the risk of both diseases. Therefore, we
considered that oral bisphosphonates might be beneﬁcial
for both osteoporosis and AMD. The current therapies for
CNVaccompaniedbyAMDandpathologicalmyopiaconsist
of repeated intravitreal injections of anti-VEGF antibodies
[1, 17]. Anti-VEGF therapy requires monthly re-injections
of the antibodies for a long period to maintain vision,
which poses a cumulative risk for ocular and systemic
complications [4–6]. Moreover, they are not suitable for the
prevention of disease. Hence, recent reviews have pointed
out the need for an optimal strategy for anti-VEGF therapy,
including combinations with other therapies [1, 20, 21].
Autoradiography with an intraperitoneal administration
of [14C]-alendronatein mice revealedthat it accumulatesnot
onlyintothebonetissue,butalsointheeye[22],particularly
in the choroidal tissues (personal communication with
Teijin Pharma. Ltd.). This may explain the delivery of oral
alendronates to CNV lesions. Alendronate is a nitrogen-
containing bisphosphonate (N-BP) which inhibits famesyl
diphosphonate synthase in the biosynthetic mevalonate
pathway. Likewise, statins are known to suppress CNV via
an inhibition of mevalonate synthesis [23]. Recent reports
have demonstrated that N-BP inhibits the expression of
VEGF, matrix metalloproteinase (MMP), and the integrin
families to inhibit angiogenesis both in vitro and in vivo
[8–11, 16]. The involvement of MMP and integrins as well
as VEGF in CNV formation has been well documented
[24]. Alendronate may suppress CNV via a direct inhibition6 Journal of Ophthalmology
of the proliferation of vascular endothelial cells [25], and
by regulating cellular angiogenic gene expression [16, 26,
27]. In addition, bisphosphonates are known to control the
inﬂammation induced by macrophages and mononuclear
cells [28–30]. Although AMD is strongly associated with sev-
eral molecules which have important roles in inﬂammation
[31, 32] ,ar e c e n tr e p o r ts u g g e s t e dt h a tm y o p i cC N Vi sn o t
associated with these molecules [33]. This may explain the
better response of AMD to bisphosphonates than myopic
CNV.
Currently, a number of bisphosphonates have been
developed, and some of them are exempt from serious
ocular adverse events [34]. The broad beneﬁcial eﬀects of
bisphosphonates are being investigated in many research
areas besides osteoporosis, especially tumorigenesis. Hence,
weconsideredthattheeﬀectsoforalbisphosphonatesmaybe
further investigated as a therapeutic drug for CNV, including
AMD and pathological myopia. Moreover, the combination
of oral bisphosphonates with anti-VEGF therapy can be
further investigated since it may reduce the number of anti-
VEGF therapy visits required.
Due to the small sample size and non-randomized con-
trolled study, a deﬁnitive conclusion may not be drawn from
these results, and further studies including a randomized
controlled trial and comparisons with other therapies such
asintravitrealranibizumabarerequiredtoconﬁrmthesafety
and eﬃcacy of bisphosphonates in the eye. However, it
is interesting that our previous study using photodynamic
therapy to treat AMD did not improve the mean visual
acuity of the patients, which might imply some advantages
of oral bisphosphonates for speciﬁc AMD patients. Our
goal is to determine whether bisphosphonates are useful
as preventative or supportive drugs for current anti-VEGF
therapy in CNV treatment. The present study gave a novel
and totally diﬀerent insight into the use of this drug class
in ophthalmology and suggested a new possibility for the
management of CNV accompanied by AMD or pathological
myopia.
5. Summary
We treated patients with choroidal neovascularization
(CNV) due to age-related macular degeneration and patho-
logical myopia with oral bisphosphonates and found their
remarkable therapeutic eﬀect on CNV for the ﬁrst time.
Our ﬁndings suggest a beneﬁcial eﬀect of bisphosphonates
in the treatment, and perhaps the prevention, of CNV for
the future.
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